EZH2 and central nervous system cancer: As the catalytic subunit of PRC2 and histone lysine methyltransferase (HMT) class enzymes, enhancer of zeste homolog 2 (EZH2) has been shown to be linked to poor prognosis and serves as a therapeutic target for various types of human cancers including breast cancer and glioma 3, 4.